TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A 2026 paper in The Lancet Healthy Longevity argues that sarcopenia should be understood as decline across the aging motor system, including the brain, nerves and muscles. The authors propose changes to research and clinical assessment, but say the suggested tests have not yet been shown to improve outcomes or lower costs.
A paper published in The Lancet Healthy Longevity argues that weakness and mobility loss in older adults should not be treated as muscle problems alone, proposing that sarcopenia also reflects age-related changes in the brain, spinal cord, nerves and their connections to muscle. The authors say the broader model could change how clinicians assess weakness, but acknowledge that the proposed measures have not yet been shown to outperform current screening or improve outcomes.
The authors say the diagnosis of sarcopenia has already shifted toward measures of strength and physical performance, including grip strength, walking speed and chair stands, because these predict falls, disability and death better than muscle mass alone. But, they argue, clinical explanations and research have continued to focus heavily on muscle wasting. The paper is by Lucas B. R. Orssatto and colleagues and is titled “Reframing sarcopenia as a disease of the ageing motor system.”
The paper’s central argument is that muscle loss accounts for only a modest share of the strength decline seen with age. People with similar muscle quantities can have different strength and mobility, the authors note, while exercise can improve physical function even when measurable muscle mass does not change. They point to movement as a coordinated process: the brain plans it, the nervous system sends signals, and muscles respond. Age-related changes at any point in that system may affect performance.
The authors suggest clinicians continue measuring strength and walking speed while also observing how quickly a person rises from a chair, whether they become unsteady during sustained effort, how dexterous their hands are, and whether walking changes while they talk. They recommend closer examination when weakness is asymmetric, rapid or out of proportion to muscle loss. They also say medication review matters: sedative and anticholinergic drugs can blunt motor drive, according to the paper.
Falls Make Mobility Assessment Urgent
The argument has practical relevance because weakness can limit everyday activities and increase vulnerability to falls. The source report says sarcopenia affects up to 29% of community-dwelling older adults, with higher rates in hospitals and residential care and among people with frailty or multiple health conditions. In Australia, falls remain a major cause of injury-related hospitalization and death: there were 253,800 fall-related hospitalizations in 2024–25, and 6,722 people died after falls in the preceding year, according to figures cited in the report.
If the authors’ model is supported by further evidence, assessment could focus more closely on which parts of the motor system may be contributing to an individual’s difficulty, rather than treating muscle mass as the main explanation. That could influence research priorities and encourage approaches that target movement and function alongside muscle. For now, this is a proposed reframing, not evidence that a new assessment or treatment has been proven to prevent falls or preserve independence.
Products Worth Considering
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Movement
In Australia, primary care has recently received a proposed algorithm for screening, assessing and managing poor muscle health, published earlier in 2026 in the Australian Journal of General Practice, according to the source report. The new paper takes up a related question: whether the explanation behind existing measures of strength and function should also change.
Orssatto and colleagues propose a five-point agenda for international working groups responsible for diagnostic criteria. Their case draws on a gap between muscle size and what a person can do: standing from a chair, for example, depends on speed and power, not simply bulk. The authors argue that power declines earlier and faster with age than muscle mass and relies in part on how effectively nerves recruit and drive muscle fibers. They call for research and clinical guidance that account for the wider motor system.
“The evidence does not fit.”
— The authors, as summarized in the Medical Xpress report
New Tests Still Need Validation
The paper presents a research and clinical proposal; it does not establish that motor-system measures improve diagnosis, prevent falls or preserve independence better than current screening. The authors say the measures they suggest have not been shown to outperform existing screens on health outcomes or cost. It is also unclear which practical tests would be sufficiently reliable for routine primary care, or how clinicians without specialist neuromuscular expertise could use them.
The report does not provide trial results demonstrating that treatments aimed at nerves or other motor-system components improve everyday function beyond existing approaches. Nor does the proposal mean muscle is unimportant: the authors argue that muscle remains part of the system, while challenging the idea that muscle loss alone explains weakness. Further studies will be needed to test the model and identify which interventions help which patients.
Research Must Test the Model
The authors call for investment in validating practical assessment tools, developing guidelines for a staged clinical approach and running trials that measure nerve as well as muscle outcomes. International working groups that set sarcopenia diagnostic criteria are a potential audience for their proposed agenda. The paper does not announce a timetable for changes to those criteria.
For patients and clinicians, the immediate point is not to replace established assessment or prescribe a new treatment based on this paper. Rather, the authors argue that persistent weakness may merit attention to movement, balance, medication and signs that warrant closer examination, in addition to muscle health. Whether this wider approach leads to more effective care will depend on the results of future validation studies and trials.
Key Questions
What is sarcopenia?
Sarcopenia refers to age-related loss of muscle, strength and physical function. The paper argues that weakness and mobility loss associated with it may involve more than muscle changes alone.
What does the motor-system explanation include?
It includes the brain, spinal cord, nerves and their connections to muscle, as well as the muscle itself. The authors say changes across this system may affect how movement is planned and produced.
Are the proposed assessment measures established tests?
No. The authors suggest observations such as chair-rise speed, unsteadiness, hand dexterity and walking while talking, but say these measures have not been shown to outperform current screens on outcomes or cost.
Does the paper show that a new treatment prevents falls?
No. It proposes a broader way to understand age-related weakness and calls for further research. The report does not describe trial evidence showing that a motor-system treatment prevents falls or preserves independence.
Source: medicalxpress.com
